samedan logo

 
 
spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

Cobra Biologics completes production of Master Cell Banks for CombiGene’s epilepsy gene therapy drug candidate

Cobra Biologics

Foundation for future commercial supply of CG01 secured with delivery of three Master Cell Banks

Lund, Sweden and Keele, UK, 18 August 2020. Cobra Biologics (Cobra), part of the Cognate BioServices family, an international CDMO manufacturer of biological materials and pharmaceuticals, and CombiGene AB (publ) (CombiGene), the leading gene therapy company in the Nordic region, today announced that Cobra has successfully produced master cell banks for the three plasmids used as starting material for CombiGene’s gene therapy CG01. Critical to assuring ‘life time’ supply of therapeutic, this represents a further milestone in the future commercial manufacture of a drug candidate designed for the treatment of drug-resistant focal epilepsy.

The three master cell banks have been developed according to Good Manufacturing Practice (GMP). GMP-compliant cell bank production assures stable and uniform populations of cells are preserved as starting material for all future batches of the three plasmids and a sufficient supply of material is readily available for the life of the product. Ensuring the quality and characteristics of the plasmids are identical at each individual production time, the master cell banks can thus be used each time CombiGene produces new plasmids for production of CG01 whether that be for future clinical studies or commercial production.

This follows the recent milestone announcement that Cobra had successfully produced and supplied all three of the plasmids that form the starting material and are key components in the production of CombiGene’s gene therapy vector, CG01. This gene therapy vector is tasked with "transporting" CG01's active substances NPY and Y2 into the patient's brain tissue.

Karin Agerman, Chief Research and Development Officer, CombiGene:"The fact that we now have the three master cell banks in place means that all further production of plasmids, used in the manufacturing of CG01, for the final preclinical and clinical studies as well as future treatments, take place from a stable and safe basis."

Peter Coleman, Chief Executive, Cobra Biologics:"The generation of DNA cell banks is the vital first step in the product commercialisation journey. Cobra is excited to continue that journey with CombiGene and their CG01 epilepsy gene therapy drug candidate."
phone +44 (0)1782 714181
web https://www.cobrabio.com/
email Cobra Biologics, Stephenson Building Keele Science Park, ST5 5SP, UK
 
Print this page
Send to a friend
   
spacer
News and Press Releases

AirBridgeCargo Airlines Expands Its Partnership With Sonoco Thermosafe To Embrace New Pegasus Uld Passive Container

AirBridgeCargo Airlines, part of Volga-Dnepr Group, expands its Master Lease Agreement with Sonoco ThermoSafe to enable its customers worldwide to transport life-saving and healthcare products within Pegasus ULD passive container (passive container – ULD capable to maintain internal temperature environment during a certain period of time without charge). The latest Sonoco addition to a sophisticated product family will guarantee secure, trackable, and reliable transportation of temperature-sensitive pharmaceutical shipments of up to 998 kg.
More info >>


White Papers

Extractables and Leachables Testing: A Risk Based Approach

RSSL

Pharmaceutical products are in contact with many external components during both manufacture and usage and small amounts of chemicals may leach from these components with a potential health risk to the patient. Extractables and leachables (E&L) studies therefore play an important role in verifying the safety of a drug product over its lifetime. Regulatory organisations such as the US Food and Drug Administration (FDA) and the European Medicines Agency (EMEA) are taking an increased interest in the interactions of various drug delivery devices, pharmaceutical product containers and medical devices with drug product and/or patient and this field is therefore growing in importance. Regulatory guidelines indicate that an extractables profile should be determined for all materials that contact the drug product. Once established, this profile can be used to determine whether any of these extractables are present as leachables within the product. If a leachable is detected, amounts can be determined using validated analytical methods, after which a biological risk can be established based on the exposure. This white paper will provide an overview of the processes used to determine extractables and leachables from plastics.
More info >>

Industry Events

12th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology

8-11 February 2021, Vienna, Austria

In continuation of the very successful scientific meetings in Budapest, Paris, Berlin, Florence, Geneva, Barcelona, Malta, Istanbul, Lisbon, Glasgow and Granada, the 12th PBP World will be held in Vienna from 8-11 Feb 2021. This every two year held conference has gained an ever increasing impact among the pharmaceutical scientists: With up to 1000 submitted abstracts and about 1300 participants it has become a well-established major meeting, attracting scientists from all over the world.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement